HomeBUSINESS
BUSINESS

Takeda Spin-Off Chordia Aims to Develop Oncology Blockbuster Drug
(Dec.4.2017)

Chordia President Hiroshi Miyake
Chordia Therapeutics, a biotech established by six former researchers of Takeda Pharmaceutical, expects that its CDC-like kinase (CLK) inhibitor in the preclinical stage would have the potential to become a 100 billion yen-blockbuster, President Hiroshi Miyake said on November 30 ...
(LOG IN FOR FULL STORY)